By Kevin E. Noonan

Uspto_seal_no_background
Among the many new requirements contained in the U.S.
Patent and Trademark Office’s recently-promulgated new rules on continuation
application filing and claim number restrictions (see links below), the Office has imposed a
deadline of February 1, 2008 for all pending applications to satisfy two
reporting requirements.  First,
applicants must identify (in every pending application) every commonly-owned
application or patent that names at least one inventor in common and was filed
or claims priority to an application that was filed within two months of the
subject application.  Second, for every
commonly-owned patent application sharing a common inventor and "substantially
overlapping" subject matter, a rebuttable presumption will arise that
there is at least one patentably-indistinct claim in each application (using a
one-way obviousness test) (see new rules notice, p. 46,785).  Although reasons can be imagined for the purpose of these requirements,
it is not unreasonable to assume that the burden imposed by these requirements
may motivate applicants to simply cancel any application that is not
sufficiently important to them to incur the expense of complying with the
reporting requirements.  It is likewise
not unreasonable to presume (in view of the Office’s invocation of the
"overwhelming" backlog of pending cases as justification for the new
rules) that this economic disincentive to maintaining what are perceived to be
"unnecessary" applications is precisely the intended purpose of these
rules.

Biotechnology_industry_organization
While heretofore strangely quiet on the subject of the
new rules (see "Breaking A Very Long Silence"), recognition of the reality of the impending
economic burden appears to have influenced the behavior of at least two major
patent interest groups.  The Intellectual
Property Owners (IPO) posted yesterday on their website the results of a
survey of 37 member organizations relating to the extent of the burden these
new rules would impose.  In addition, reliable sources have told Patent Docs that the
Biotechnology Industrial Organization (BIO), joined by IPO and perhaps other
groups, recently met with Patent Office officials to discuss the extraordinary
burdens of complying with these rules.  As a result, these sources tell Patent Docs that the Office has promised
to revisit this aspect of the recent rulemaking, and to either modify the Ipo_2
rule
or extend the deadline.  Although either
would be welcome, the Office’s acknowledgement of the justification of IPO’s
and BIO’s complaints appears to contradict their representations to the Office
of Management and Budget (and that Office’s subsequent decision) that the rules
imposed no significant economic impact.

It is unlikely that there will be any major retrenchment
of the new rules absent court action (which the major organizations have
abdicated to a sole inventor in a single action, and which has withdrawn a
motion for an injunction or stay of implementing the rules) or a change in the
administration.  The possibility that the
rules will be relaxed is, however, consistent with this Administration’s
penchant for taking and pressing extreme positions with little factual
justification, and retrenching only when faced with public pressure (political
or otherwise).  This track record
suggests that members of the patent community, including the patent bar, had
better get busy if they will have any hope of adequately protecting U.S. patent
rights in the face of a Patent Office administration that seems openly hostile.

For additional articles in this series, please see:

For additional information on this and other related topics, please see:

Posted in

One response to “Is the Patent Office Starting to Blink?”

  1. Inquiring Mind Avatar
    Inquiring Mind

    Thanks very much for the PatentDocs post of September 28, alerting us to the new answer in the updated PTO FAQ which clarifies that divisional applications can not be filed for claims that have been examined in an IPER, apparently regardless of whether the claims have subsequently been restricted during the U.S. national phase examination. This means that in order to be able to prosecute these claims, we will need to file continuing applications before November 1 in a very large percentage of the application families in our portfolio, or we will lose the opportunity to prosecute these claims. This is going to require a large number of additional filings before the deadline–I hope we can make it. Thanks again for alerting us to (yet another) draconian aspect of these rules, as we had overlooked this even after several readings of the rules.

    Like

Leave a comment